In children, radiological incidence of primary ES was reported as 1-48% with a male-female ratio of 1.4:1.0. [4] PES may be associated with variable clinical conditions ranging from the occasional discovery of a clinically asymptomatic pouch within the sella turcica to severe intracranial hypertension and rhinorrhea. [5] The need for replacement hormone therapy in PES, as in other syndromes that may cause hypopituitarism, must be assessed for every single hormone, including growth hormone (GH). [6, 7] Shulman et al. reported 24% of children undergoing CT scanning for evaluation of GHD had an ES. [8] Cacciari et al. reported an incidence of 8.8% in cases of isolated GHD. [9] In children with isolated GHD, although anatomical abnormalities of the genes involved in the GH axis increasingly recognized, many cases of GHD do not have a well-defined etiology and are classified as idiopathic. The aim of our study was to determine whether or not the presence of ES could allow some changes in the GH responses of the isolated GHD patients.
Materials and Methods
In the present study, we included a cohort of 59 short stature children and adolescents with idiopathic GHD. According to CT finding, they classified into 2 groups: (group 1) included 40 children with normal sella and 19 children (group 2) with ES. They were selected over 2 years period. All patients were referred from different schools all over Egypt to the GH National Committee of the school health insurance, where they were diagnosed, provided by GH and followed in association with the growth unit of the Diabetes Endocrine Metabolism Pediatric Unit (DEMPU), Children Hospital, Cairo University. They were subjected to GH treatment for a minimum period of 1 year and a maximum of 2 years.
All patients had the inclusion criteria of a stature more than 2 SD below the mean and if available, a growth velocity (monitored over 6-12 months) below the tenth centile for age and sex. All patients had peak GH level below 10 ng/ml by two provocation tests (Clonidine and insulin tolerance tests). Patients with short stature due to chronic systemic disease, malnutrition, Turner syndrome, bone dysplasias or prenatal causes, or their CT finding revealed an acquired space occupying lesions such as brain tumor, cyst or hydrocephalus or patients showed either atrophic sella or a hypoplastic pituitary gland diagnosed by cranial CT scan, were excluded.
Methods
Informed consent was taken from the parents of children; then all cases were subjected to the following.
Full history taking and clinical examinations were done.
Full anthropometric assessment was also done. Height was measured twice and neared to the next millimeter using Harpenden Stadiometer, height velocity in cm/year is the variable that describes the patient's 1-year velocity and plotting it in the mid-year interval. Sitting height was also measured using Harpenden sitting height apparatus. [10] Lower segment was calculated by subtraction of sitting height from height, and then from these two measurements, upper to lower segment ratio was derived (US/LS). Weight of the patients was measured using electronic balances and recorded in decimal of kilogram. Puberty was assessed by rating the breast development in girls, genital developments in boys, pubic and axillary hair development in both sexes, according to Tanner's classification. [11] All anthropometric procedures were performed at baseline before treatment and at follow-up by the same observer at the same time of the day (9 a.m.-1 p.m.) in the growth clinic of (DEMPU).
Age-related normal standards for GHD patients were calculated from tables of Tanner and Whitehouse. [12] Skeletal maturity was determined by the same observer from an X-ray of the left wrist and hand (Tanner Whitehouse no. 2 method).
Laboratory investigations included the following: DSL-5600 IGF-1 (IRMA) was included in a sample extraction step in which IGF-1 was separated from its binding protein in serum. This step is considered to be essential for accurate determination of IGF1. [13, 14] Treatment protocol All patients received biosynthetic GH therapy.
All patients received rhGH with a standard dose of 20 IU/m 2 /week. The calculated dose per week was divided for 6 days and given subcutaneously at night. Puberty was not induced by giving sex hormones during GH treatment, since the treatment was started relatively late in these patients. All the patients accepted postponing induction of puberty after explanation by the physician. [15, 16] 
Follow-up
Patients were followed for a minimum period of 1 year and for a maximum of 2 years. Every year, the surface area of each patient was calculated, and the dose of GH was adjusted to keep the therapeutic dose at 20 IU/m 2 /week (equivalent to 0.2 mg/kg/week) for GHD.
Response to GH therapy was judged on data obtained from auxological assessment.
Compliance to therapy is continuously verified by more than one parameter, e.g., height velocity, asking the parents about mode of injection and dosing, counting the empty vials and sometimes by analysis of serum IGF-1. The deviation of individual IGF-1 and IGFBP-3 values from the means for age and sex was calculated in standard deviation score (Z score) and subsequently used in statistical analysis. The laboratory of DEMPU, Cairo University children's Hospital, provided the mean values for IGF-1 and IGFBP-3.
Statistical analysis
The SPSS software computer program was used for data analysis. Quantitative data were presented as mean ± SD, range, frequencies, and qualitative data as percentage. 
Results
Descriptive data are presented in Table 1 for the studied cases. The study included 59 isolated GHD children; they were classified into 2 groups: 40 patients with normal sella (group 1) and 19 patients with When comparing pre-and the two post-treatments HTSD results of the studied cases, all showed significant changes after GH therapy [ Table 4 ]. Table 5 shows the results of related variables pre-and post-treatment in both groups. Significant improvement was observed in all variables of the two groups of the study.
Discussion
The clinical picture in patients with PES is often quite complex and not always possible to dissect symptoms and biochemical findings that are the consequences of the ES from those casually found that are merely the Indeed, growth failure is the major presenting sign of GHD in children. [17] However, to our knowledge, no studies have been reported so far to allow a detailed therapeutic picture of patients with idiopathic GH deficiency with PES.
The aim of our study was to determine whether or not the presence of ES could allow some changes in the GH responses of the isolated GHD patients.
In the present study, the frequency of an ES was significantly high in male than female, this result was in agreement with others. [4] This finding cannot be explained by a conclusive explanation. It is questioned whether this can be answered by genetic factor "the postulated greater vulnerability of male to exogenous insult. There was no significant difference between pre-pubertal and pubertal patients in both groups. Furthermore, there was no significant difference in duration of delay of treatment or the age of starting GH therapy. Our study showed a significant decrease in body weight in group 2. This was in contrast to the result of Del Monte et al. [18] who reported that overweight were frequently recorded in cases with ES.
In general, there was no other significant difference between cases with or without ES in auxological features at the start at the study. 
Conclusion
This is the first observational prospective study to investigate the outcome of subjects with childhood isolated GHD with or without ES. Our study showed a significant decrease in body weight in case with ES. However, in our opinion, our group of subjects showed similar clinical characteristics. Our data, in fact, showed a similar stature outcome in the two treatment groups.
